Switch Therapeutics Inc. — Form D/A
Switch Therapeutics Inc. of SOUTH SAN FRANCISCO, CA, a company, filed a Form D amendment with the SEC on 2022-11-17. The offering totals $36.0M, of which $23.3M was reported sold. Industry: Other.
Offering
- Filed: 2022-11-17
- Form: D/A
- Accession: 0001947761-22-000002
- Industry: Other
- Exemptions: 06b
- Total offering: $36.0M
- Amount sold: $23.3M
- Remaining: $12.7M
- Investors: 15
- Date of first sale: 2022-09-27
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-460733
Issuer
- Name: Switch Therapeutics Inc.
- CIK: 0001947761
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 241 E HARRIS AVE, SOUTH SAN FRANCISCO, CA, 94080
- Phone: (415) 518-9678
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Deepshikha Datta | Director | South San Francisco, CA |
| Alicia Irurzun-Lafitte | Director | South San Francisco, CA |
| DYLAN MORRIS | Director | Watertown, MA |
| Kevin Zhang | Director | Los Angeles, CA |
| Deepshikha Datta | Executive Officer | South San Francisco, CA |
| Si-Ping Han | Executive Officer | South San Francisco, CA |
Other filings by this issuer (1)
More